Home › Sepsis › North Carolina › Winston-Salem
Sepsis clinical trials in Winston-Salem, NC
4 studies for Sepsis are looking for participants at sites in and around Winston-Salem (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
RecruitingPhase 2
- Research Site, Winston-Salem
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
RecruitingPhase 4
- Wake Forest University Health Sciences, Winston-Salem
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
RecruitingPhase 1/2Healthy volunteers welcome
- Research Site, Winston-Salem
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
RecruitingPhase 3
- Novant Healthcare, Winston-Salem
About Sepsis
Sepsis is a serious illness and can lead to a life threatening condition called septic shock. Read about symptoms, treatment and risk factors for sepsis.
More about Sepsis on MedlinePlus
Sepsis trials in other cities
- Philadelphia, PA7 studies
- Baltimore, MD6 studies
- Boston, MA5 studies
- San Francisco, CA4 studies
- Gainesville, FL3 studies
- St. Louis, MO3 studies
- Chicago, IL3 studies
- Rochester, MN3 studies
- Seattle, WA3 studies
- Oklahoma City, OK3 studies
Other studies in Winston-Salem
- Cancer (all types)19 studies
- Acute Myeloid Leukemia18 studies
- Multiple Myeloma14 studies
- Breast Cancer14 studies
- Cardiovascular Disease14 studies
- Non-Small Cell Lung Cancer12 studies
- COPD10 studies
- Ovarian Cancer10 studies
- Type 2 Diabetes9 studies
- Myelodysplastic Syndromes9 studies
- Glioblastoma8 studies
- Chronic Lymphocytic Leukemia8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.